Rezolute Inc (RZLT)

$3.20 -0.09 (-2.74%)
Market Cap 314.85M
Revenue (ttm) 0.00
Net Income (ttm) -74.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,506,800
Avg Vol 8,409,146
Day's Range N/A - N/A
Shares Out 95.70M
Stochastic %K 22%
Beta 0.46
Analysts Strong Sell
Price Target $4.75

Company Profile

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 206 4507
Address:
275 Shoreline Drive, Suite 500, Redwood City, United States
EvCe
EvCe Feb. 23 at 9:09 AM
$RZLT
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 6:38 PM
$RZLT RSI: 48.78, MACD: 0.0085 Vol: 0.24, MA20: 3.33, MA50: 3.05 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Monty3030
Monty3030 Feb. 21 at 4:17 AM
$RZLT New Update 11.32 Days to Cover 26.68% Short Interest
0 · Reply
Monty3030
Monty3030 Feb. 20 at 5:40 PM
$RZLT Short Interest Ratio 7.14 Days to Cover Short Interest % Float 26.68 %
0 · Reply
EvCe
EvCe Feb. 20 at 8:52 AM
$RZLT uh oh …adding … slow long run
0 · Reply
Dan_o
Dan_o Feb. 19 at 5:27 AM
$CALC I cannot think of a more motivated group of people than the current management. They own 52% of the shares or 7.4 mil shares. Before the dip the value was $37 mil and current value is $4 mil. They have a cost bases of about $18 mil. If they could only learn from $RZLT management. Their share price dropped from $10 to $1 in December. Management stepped in and purchased the stock at a deep discount like we are doing. In a little over a month and a half their price per share has peaked at $4 and is holding above $3.5 a share.
1 · Reply
PepCF
PepCF Feb. 17 at 2:44 PM
$RZLT Why is it down?
2 · Reply
Monty3030
Monty3030 Feb. 16 at 7:49 PM
$RZLT From the mouth of the CEO!!
1 · Reply
Monty3030
Monty3030 Feb. 16 at 7:48 PM
$RZLT https://www.statnews.com/sponsor/2026/02/09/the-conundrum-of-false-negative-clinical-studies-in-ultra-rare-diseases/ STAT highlights false-negative trials in ultra-rare diseases and cites ersodetug/CHI — where biology and real-world benefit exist despite a missed endpoint. Supports the “design failed, not the drug” thesis. Let's see where we go this week.
0 · Reply
oaksapollo
oaksapollo Feb. 14 at 7:03 PM
$RZLT For the real investors here - do some reading on randomized withdrawal study. It's the perfect study design for Rezolute's current predicament. They can just re-consent and boom, all subjects are already enrolled and stable on ersodetug, just re-randomize and you're off and running. I'd imagine they want to get FDA alignment on this first, but if FDA agrees, I suspect we could be looking at a second cHI readout in late 2026. Remember, the sunRIZE study took 17 months to enroll. With randomized withdrawal, you eliminate that huge time sink.
1 · Reply
Latest News on RZLT
RZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Feb 19, 2026, 9:51 AM EST - 4 days ago

RZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Feb 17, 2026, 7:23 PM EST - 6 days ago

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Feb 13, 2026, 10:13 AM EST - 10 days ago

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Feb 12, 2026, 4:05 PM EST - 11 days ago

Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Feb 10, 2026, 10:51 AM EST - 13 days ago

SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating

Feb 9, 2026, 3:19 PM EST - 14 days ago

Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating

SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Feb 5, 2026, 5:09 PM EST - 18 days ago

SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 19 days ago

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Alger Small Cap Growth Fund Q4 2025 Portfolio Update

Jan 26, 2026, 3:54 AM EST - 4 weeks ago

Alger Small Cap Growth Fund Q4 2025 Portfolio Update

EXAS GH NBIS NTRA WIX

INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Jan 25, 2026, 8:21 PM EST - 4 weeks ago

INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Jan 16, 2026, 10:27 AM EST - 5 weeks ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Jan 8, 2026, 1:12 PM EST - 6 weeks ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

Jan 7, 2026, 7:00 AM EST - 6 weeks ago

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

Jan 3, 2026, 7:41 AM EST - 7 weeks ago

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

Dec 31, 2025, 12:10 PM EST - 7 weeks ago

INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

Dec 19, 2025, 10:08 AM EST - 2 months ago

REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

RZLT: Rezolute, Inc. Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

Dec 17, 2025, 4:31 PM EST - 2 months ago

RZLT: Rezolute, Inc. Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Dec 12, 2025, 3:00 PM EST - 2 months ago

RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure

Dec 11, 2025, 7:59 PM EST - 2 months ago

Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure

Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT

Dec 11, 2025, 2:39 PM EST - 2 months ago

Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT

Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript

Dec 11, 2025, 2:22 PM EST - 2 months ago

Rezolute, Inc. (RZLT) Discusses Phase 3 sunRIZE Study Results and Challenges in Congenital Hyperinsulinism Transcript

BREAKING: Rezolute, Inc. Shares Down Over 85%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Dec 11, 2025, 10:39 AM EST - 2 months ago

BREAKING: Rezolute, Inc. Shares Down Over 85%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Rezolute's rare disease drug fails main goal in late-stage trial

Dec 11, 2025, 7:05 AM EST - 2 months ago

Rezolute's rare disease drug fails main goal in late-stage trial

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Dec 11, 2025, 7:00 AM EST - 2 months ago

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute: sunRIZE And upLIFT Trials Could Drive The Next Move

Dec 8, 2025, 9:23 PM EST - 2 months ago

Rezolute: sunRIZE And upLIFT Trials Could Drive The Next Move

Rezolute, Inc. (RZLT) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism Transcript

Nov 10, 2025, 7:51 PM EST - 3 months ago

Rezolute, Inc. (RZLT) Discusses Clinical Progress and Market Opportunity for Ersodetug in Hyperinsulinism Transcript

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 5:30 PM EST - 3 months ago

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 3 months ago

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Nov 5, 2025, 7:30 AM EST - 3 months ago

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Rezolute to Participate in Upcoming Investor Conferences

Oct 15, 2025, 8:00 AM EDT - 4 months ago

Rezolute to Participate in Upcoming Investor Conferences

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Sep 17, 2025, 4:05 PM EDT - 5 months ago

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug

Sep 16, 2025, 4:36 PM EDT - 5 months ago

Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug

Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 12, 2025, 9:38 AM EDT - 5 months ago

Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

Sep 2, 2025, 7:30 AM EDT - 6 months ago

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

Aug 20, 2025, 7:30 AM EDT - 6 months ago

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Jul 22, 2025, 7:30 AM EDT - 7 months ago

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Jul 9, 2025, 7:30 AM EDT - 8 months ago

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 28, 2025, 8:00 AM EDT - 9 months ago

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 10 months ago

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

May 5, 2025, 8:00 AM EDT - 10 months ago

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

EvCe
EvCe Feb. 23 at 9:09 AM
$RZLT
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 6:38 PM
$RZLT RSI: 48.78, MACD: 0.0085 Vol: 0.24, MA20: 3.33, MA50: 3.05 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Monty3030
Monty3030 Feb. 21 at 4:17 AM
$RZLT New Update 11.32 Days to Cover 26.68% Short Interest
0 · Reply
Monty3030
Monty3030 Feb. 20 at 5:40 PM
$RZLT Short Interest Ratio 7.14 Days to Cover Short Interest % Float 26.68 %
0 · Reply
EvCe
EvCe Feb. 20 at 8:52 AM
$RZLT uh oh …adding … slow long run
0 · Reply
Dan_o
Dan_o Feb. 19 at 5:27 AM
$CALC I cannot think of a more motivated group of people than the current management. They own 52% of the shares or 7.4 mil shares. Before the dip the value was $37 mil and current value is $4 mil. They have a cost bases of about $18 mil. If they could only learn from $RZLT management. Their share price dropped from $10 to $1 in December. Management stepped in and purchased the stock at a deep discount like we are doing. In a little over a month and a half their price per share has peaked at $4 and is holding above $3.5 a share.
1 · Reply
PepCF
PepCF Feb. 17 at 2:44 PM
$RZLT Why is it down?
2 · Reply
Monty3030
Monty3030 Feb. 16 at 7:49 PM
$RZLT From the mouth of the CEO!!
1 · Reply
Monty3030
Monty3030 Feb. 16 at 7:48 PM
$RZLT https://www.statnews.com/sponsor/2026/02/09/the-conundrum-of-false-negative-clinical-studies-in-ultra-rare-diseases/ STAT highlights false-negative trials in ultra-rare diseases and cites ersodetug/CHI — where biology and real-world benefit exist despite a missed endpoint. Supports the “design failed, not the drug” thesis. Let's see where we go this week.
0 · Reply
oaksapollo
oaksapollo Feb. 14 at 7:03 PM
$RZLT For the real investors here - do some reading on randomized withdrawal study. It's the perfect study design for Rezolute's current predicament. They can just re-consent and boom, all subjects are already enrolled and stable on ersodetug, just re-randomize and you're off and running. I'd imagine they want to get FDA alignment on this first, but if FDA agrees, I suspect we could be looking at a second cHI readout in late 2026. Remember, the sunRIZE study took 17 months to enroll. With randomized withdrawal, you eliminate that huge time sink.
1 · Reply
JPVSLIFE
JPVSLIFE Feb. 13 at 10:13 PM
$RZLT what a ride!!!! Looking for some options action.
0 · Reply
Monty3030
Monty3030 Feb. 13 at 9:01 PM
$RZLT Over 6 million shares traded! Huge buy at the end of today.
0 · Reply
StreetwiseReports
StreetwiseReports Feb. 13 at 8:57 PM
Biotech Company Advances Breakthrough Hyperinsulinism Treatment https://ow.ly/XIsn50Yfoex Rezolute Inc. ($RZLT:NASDAQ), a late-stage company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), reports its financial results and provides a business update for the three months ending December 31, 2025. Read why one analyst considers the stock a Buy.
0 · Reply
JuliusW
JuliusW Feb. 13 at 6:19 PM
$RZLT $CADL holding
0 · Reply
Rangodown
Rangodown Feb. 13 at 6:17 PM
$RZLT she just keeps going what a ride, got in at 1.3 has not been a single stress along the way!
1 · Reply
MrBlockchain
MrBlockchain Feb. 13 at 6:16 PM
$RZLT Huh, would you look at that. 😄
0 · Reply
Smiles_P
Smiles_P Feb. 13 at 5:45 PM
$RZLT would have loved to see some more specifics, but confirming FDA meeting and continued treatment is big and will keep this slow rise going…
0 · Reply
PepCF
PepCF Feb. 13 at 5:13 PM
$RZLT I’m playing it safe with a target of 5 or 6, but imagine if it goes all the way to 10.
0 · Reply
impossiblepub
impossiblepub Feb. 13 at 4:59 PM
$RZLT so quiet in here, and this thing just keeps going up. 1.51 avg doesnt look bad at all.
0 · Reply
niock
niock Feb. 13 at 2:44 PM
$RZLT
0 · Reply
Chefbyday
Chefbyday Feb. 13 at 1:13 PM
$RZLT she want to go! 💰
1 · Reply